Structure of the Neisseria Adhesin Complex Protein (ACP) and its role as a novel lysozyme inhibitor

PLoS Pathogens

Volumn 13, Issue 6, 2017, Pages

  Humbert, María Victoria ^a   Awanye, Amaka Marian ^b   Lian, Lu Yun ^c   Derrick, Jeremy P ^b   Christodoulides, Myron ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; ENZYME INHIBITOR; LYSOZYME; BACTERIAL PROTEIN; MENINGOCOCCUS VACCINE;

ACP GENE; ARTICLE; BACTERIAL GENE; BACTERIAL OUTER MEMBRANE; BRUCELLA ABORTUS; CRYSTALLIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE INACTIVATION; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; MOUSE; NEISSERIA; NEISSERIA GONORRHOEAE; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POLYMERASE CHAIN REACTION; PROTEIN MOTIF; PROTEIN STRUCTURE; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; WESTERN BLOTTING; X RAY CRYSTALLOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; LEPORIDAE; METABOLISM;

ADHESINS, BACTERIAL; ANIMALS; BACTERIAL PROTEINS; HOST-PATHOGEN INTERACTIONS; HUMANS; MENINGOCOCCAL VACCINES; MURAMIDASE; NEISSERIA; NEISSERIA MENINGITIDIS; RABBITS;

EID: 85021810741     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006448     Document Type: Article

References (65)

1. Callewaert L, Van Herreweghe JM, Vanderkelen L, Leysen S, Voet A, Michiels CW, Guards of the great wall: bacterial lysozyme inhibitors. Trends Microbiol. 2012;20(10):501–10. doi: 10.1016/j.tim.2012.06.005 22840966.
2. McNabb PC, Tomasi TB, Host defense mechanisms at mucosal surfaces. Annu Rev Microbiol. 1981;35:477–96. doi: 10.1146/annurev.mi.35.100181.002401 7027905.
3. Cole AM, Dewan P, Ganz T, Innate antimicrobial activity of nasal secretions. Infect Immun. 1999;67(7):3267–75. 10377100; PubMed Central PMCID: PMC116505.
4. Jacquot J, Hayem A, Galabert C, Functions of proteins and lipids in airway secretions. Eur Respir J. 1992;5(3):343–58. 1572448.
5. Peeters T, Vantrappen G, The Paneth cell: a source of intestinal lysozyme. Gut. 1975;16(7):553–8. 1167179; PubMed Central PMCID: PMC1410982.
6. Murakami K, Lagarde M, Yuki Y, Identification of minor proteins of human colostrum and mature milk by two-dimensional electrophoresis. Electrophoresis. 1998;19(14):2521–7. doi: 10.1002/elps.1150191427 9820977.
7. Selsted ME, Martinez RJ, Lysozyme: primary bactericidin in human plasma serum active against Bacillus subtilis. Infect Immun. 1978;20(3):782–91. 97236; PubMed Central PMCID: PMC421927.
8. Davis KM, Weiser JN, Modifications to the peptidoglycan backbone help bacteria to establish infection. Infect Immun. 2011;79(2):562–70. doi: 10.1128/IAI.00651-10 21041496; PubMed Central PMCID: PMC3028845.
9. Clarke CA, Scheurwater EM, Clarke AJ, The vertebrate lysozyme inhibitor Ivy functions to inhibit the activity of lytic transglycosylase. J Biol Chem. 2010;285(20):14843–7. doi: 10.1074/jbc.C110.120931 20351104; PubMed Central PMCID: PMC2865275.
10. Monchois V, Abergel C, Sturgis J, Jeudy S, Claverie JM, Escherichia coli ykfE ORFan gene encodes a potent inhibitor of C-type lysozyme. J Biol Chem. 2001;276(21):18437–41. doi: 10.1074/jbc.M010297200 11278658.
11. Callewaert L, Aertsen A, Deckers D, Vanoirbeek KG, Vanderkelen L, Van Herreweghe JM, et al. A new family of lysozyme inhibitors contributing to lysozyme tolerance in gram-negative bacteria. PLoS Pathog. 2008;4(3):e1000019. doi: 10.1371/journal.ppat.1000019 18369469; PubMed Central PMCID: PMC2267010.
12. Russell AB, Hood RD, Bui NK, LeRoux M, Vollmer W, Mougous JD, Type VI secretion delivers bacteriolytic effectors to target cells. Nature. 2011;475(7356):343–7. doi: 10.1038/nature10244 21776080; PubMed Central PMCID: PMC3146020.
13. Sethi D, Mahajan S, Singh C, Lama A, Hade MD, Gupta P, et al. Lipoprotein LprI of Mycobacterium tuberculosis Acts as a Lysozyme Inhibitor. J Biol Chem. 2016;291(6):2938–53. doi: 10.1074/jbc.M115.662593 26589796; PubMed Central PMCID: PMC4742756.
14. Dillard JP, Hackett KT, Mutations affecting peptidoglycan acetylation in Neisseria gonorrhoeae and Neisseria meningitidis. Infect Immun. 2005;73(9):5697–705. doi: 10.1128/IAI.73.9.5697-5705.2005 16113287; PubMed Central PMCID: PMC1231103.
15. Veyrier FJ, Williams AH, Mesnage S, Schmitt C, Taha MK, Boneca IG, De-O-acetylation of peptidoglycan regulates glycan chain extension and affects in vivo survival of Neisseria meningitidis. Mol Microbiol. 2013;87(5):1100–12. doi: 10.1111/mmi.12153 23373517.
16. Rouphael NG, Stephens DS, Neisseria meningitidis: biology, microbiology, and epidemiology. Methods MolBiol. 2012;799:1–20. doi: 10.1007/978-1-61779-346-2_1 21993636
17. Hung MC, Christodoulides M, The biology of Neisseria adhesins. Biology (Basel). 2013;2(3):1054–109. doi: 10.3390/biology2031054 24833056
18. Harkness AH, The pathology of gonorrhoea. British Journal Of Venereal Diseases. 1948;24:137–47. 18099876
19. Handsfield HH, Sparling PF, Mandell GL, Bennett JE, Dolin R, Neisseria gonorrhoeae. In: Mandell, Douglas & Bennett's Principles and Practice of Infectious Diseases, Vol2. 4th ed.New York: Churchill Livingstone; 1995. p. 1909–26.
20. Hung MC, Heckels JE, Christodoulides M, The adhesin complex protein (ACP) of Neisseria meningitidis is a new adhesin with vaccine potential. mBio. 2013;4(2):mBio 4(2) pii: e00041–13. 10.1128/mBio.-13. doi: 10.1128/mBio.00041-13 23443003; PubMed Central PMCID: PMC3585444.
21. Holm L, Rosenstrom P, Dali server: conservation mapping in 3D. Nucleic Acids Res. 2010;38(Web Server issue):W545–9. doi: 10.1093/nar/gkq366 20457744; PubMed Central PMCID: PMC2896194.
22. Leysen S, Van Herreweghe JM, Callewaert L, Heirbaut M, Buntinx P, Michiels CW, et al. Molecular basis of bacterial defense against host lysozymes: X-ray structures of periplasmic lysozyme inhibitors PliI and PliC. J Mol Biol. 2011;405(5):1233–45. doi: 10.1016/j.jmb.2010.12.007 21146533.
23. Um SH, Kim JS, Kim K, Kim N, Cho HS, Ha NC, Structural basis for the inhibition of human lysozyme by PliC from Brucella abortus. Biochemistry. 2013;52(51):9385–93. doi: 10.1021/bi401241c 24308818.
24. Yum S, Kim MJ, Xu Y, Jin XL, Yoo HY, Park JW, et al. Structural basis for the recognition of lysozyme by MliC, a periplasmic lysozyme inhibitor in Gram-negative bacteria. Biochem Biophys Res Commun. 2009;378(2):244–8. doi: 10.1016/j.bbrc.2008.11.039 19028453.
25. During K, Porsch P, Mahn A, Brinkmann O, Gieffers W, The non-enzymatic microbicidal activity of lysozymes. FEBS Lett. 1999;449(2–3):93–100. 10338111.
26. Herbert S, Bera A, Nerz C, Kraus D, Peschel A, Goerke C, et al. Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci. PLoS Pathog. 2007;3(7):e102. doi: 10.1371/journal.ppat.0030102 17676995; PubMed Central PMCID: PMC1933452.
27. Nash JA, Ballard TN, Weaver TE, Akinbi HT, The peptidoglycan-degrading property of lysozyme is not required for bactericidal activity in vivo. J Immunol. 2006;177(1):519–26. 16785549.
28. Chaudhury S, Berrondo M, Weitzner BD, Muthu P, Bergman H, Gray JJ, Benchmarking and analysis of protein docking performance in Rosetta v3.2. PLoS One. 2011;6(8):e22477. doi: 10.1371/journal.pone.0022477 21829626; PubMed Central PMCID: PMC3149062.
29. Laver JR, Pounce ZC, Read RC. Factors influencing in vitro transformation efficiency of Neisseria lactamica. American Society for Microbiology Microbe; June 16–20; Boston 2016. Poster SU-692.
30. Van Herreweghe JM, Vanderkelen L, Callewaert L, Aertsen A, Compernolle G, Declerck PJ, et al. Lysozyme inhibitor conferring bacterial tolerance to invertebrate type lysozyme. Cell Mol Life Sci. 2010;67(7):1177–88. doi: 10.1007/s00018-009-0241-x 20049505.
31. Vanderkelen L, Van Herreweghe JM, Vanoirbeek KG, Baggerman G, Myrnes B, Declerck PJ, et al. Identification of a bacterial inhibitor against g-type lysozyme. Cell Mol Life Sci. 2011;68(6):1053–64. doi: 10.1007/s00018-010-0507-3 20734102.
32. Lu D, Shang G, Zhang H, Yu Q, Cong X, Yuan J, et al. Structural insights into the T6SS effector protein Tse3 and the Tse3-Tsi3 complex from Pseudomonas aeruginosa reveal a calcium-dependent membrane-binding mechanism. Mol Microbiol. 2014;92(5):1092–112. doi: 10.1111/mmi.12616 24724564.
33. Revington M, Semesi A, Yee A, Arrowsmith CH, Shaw GS, The solution structure of the protein ydhA from Escherichia coli. J Biomol NMR. 2006;35(4):295–300. doi: 10.1007/s10858-006-9032-y 16937244.
34. Ragland SA, Schaub RE, Hackett KT, Dillard JP, Criss AK, Two lytic transglycosylases in Neisseria gonorrhoeae impart resistance to killing by lysozyme and human neutrophils. Cell Microbiol. 2016. doi: 10.1111/cmi.12662 27597434.
35. Le CF, Fang CM, Sekaran SD, Intracellular Targeting Mechanisms by Antimicrobial Peptides. Antimicrob Agents Chemother. 2017;61(4). doi: 10.1128/AAC.02340-16 28167546; PubMed Central PMCID: PMC5365711.
36. Omardien S, Brul S, Zaat SA, Antimicrobial Activity of Cationic Antimicrobial Peptides against Gram-Positives: Current Progress Made in Understanding the Mode of Action and the Response of Bacteria. Front Cell Dev Biol. 2016;4:111. doi: 10.3389/fcell.2016.00111 27790614; PubMed Central PMCID: PMC5063857.
37. Clifton LA, Ciesielski F, Skoda MW, Paracini N, Holt SA, Lakey JH, The Effect of Lipopolysaccharide Core Oligosaccharide Size on the Electrostatic Binding of Antimicrobial Proteins to Models of the Gram Negative Bacterial Outer Membrane. Langmuir. 2016;32(14):3485–94. doi: 10.1021/acs.langmuir.6b00240 27003358; PubMed Central PMCID: PMC4854487.
38. Kucharska I, Liang B, Ursini N, Tamm LK, Molecular Interactions of Lipopolysaccharide with an Outer Membrane Protein from Pseudomonas aeruginosa Probed by Solution NMR. Biochemistry. 2016;55(36):5061–72. doi: 10.1021/acs.biochem.6b00630 27532487.
39. McGuinness BT, Clarke IN, Lambden PR, Barlow AK, Poolman JT, Jones DM, et al. Point mutation in meningococcal porA gene associated with increased endemic disease. Lancet. 1991;337:514–7. 1705642
40. Williams JN, Jones GR, Christodoulides M, Heckels JE, Serological correlates of protection against meningococci in a cohort of university students before and during an outbreak of serogroup C infection. Journal of Infectious Diseases. 2003;187:1433–41. doi: 10.1086/374648 12717625
41. Williams JN, Skipp PJ, O'Connor CD, Christodoulides M, Heckels JE, Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates. Infect Immun. 2009;77(11):5080–9. doi: 10.1128/IAI.00701-09 19737898
42. Heckels JE, The surface properties of Neisseria gonorrhoeae: isolation of the major components of the outer membrane. JGenMicrobiol. 1977;99:333–41.
43. Williams JN, Skipp PJ, Humphries HE, Christodoulides M, O'Connor CD, Heckels JE, Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant. Infection and Immunity. 2007;75(3):1364–72. doi: 10.1128/IAI.01424-06 17158897
44. Rusniok C, Vallenet D, Floquet S, Ewles H, Mouze-Soulama C, Brown D, et al. NeMeSys: a biological resource for narrowing the gap between sequence and function in the human pathogen Neisseria meningitidis. Genome Biol. 2009;10(10):R110. doi: 10.1186/gb-2009-10-10-r110 19818133; PubMed Central PMCID: PMC2784325.
45. Stohl EA, Seifert HS, The recX gene potentiates homologous recombination in Neisseria gonorrhoeae. Molecular Microbiology. 2001;40(6):1301–10. 11442829
46. Echenique-Rivera H, Muzzi A, Del Tordello E, Seib KL, Francois P, Rappuoli R, et al. Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival. Plos Pathogens. 2011;7(5).
47. Winter G, Lobley CM, Prince SM, Decision making in xia2. Acta Crystallogr D Biol Crystallogr. 2013;69(Pt 7):1260–73. doi: 10.1107/S0907444913015308 23793152; PubMed Central PMCID: PMC3689529.
48. Kabsch W, Xds. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 2):125–32. doi: 10.1107/S0907444909047337 20124692; PubMed Central PMCID: PMC2815665.
49. Evans PR, Murshudov GN, How good are my data and what is the resolution?Acta Crystallogr D Biol Crystallogr. 2013;69(Pt 7):1204–14. doi: 10.1107/S0907444913000061 23793146; PubMed Central PMCID: PMC3689523.
50. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr. 2011;67(Pt 4):235–42. doi: 10.1107/S0907444910045749 21460441; PubMed Central PMCID: PMC3069738.
51. Terwilliger TC, Adams PD, Read RJ, McCoy AJ, Moriarty NW, Grosse-Kunstleve RW, et al. Decision-making in structure solution using Bayesian estimates of map quality: the PHENIX AutoSol wizard. Acta Crystallogr D Biol Crystallogr. 2009;65(Pt 6):582–601. doi: 10.1107/S0907444909012098 19465773; PubMed Central PMCID: PMC2685735.
52. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 2):213–21. doi: 10.1107/S0907444909052925 20124702; PubMed Central PMCID: PMC2815670.
53. Terwilliger TC, Grosse-Kunstleve RW, Afonine PV, Moriarty NW, Zwart PH, Hung LW, et al. Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. Acta Crystallogr D Biol Crystallogr. 2008;64(Pt 1):61–9. doi: 10.1107/S090744490705024X 18094468; PubMed Central PMCID: PMC2394820.
54. Emsley P, Lohkamp B, Scott WG, Cowtan K, Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 4):486–501. doi: 10.1107/S0907444910007493 20383002; PubMed Central PMCID: PMC2852313.
55. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr. 2011;67(Pt 4):355–67. doi: 10.1107/S0907444911001314 21460454; PubMed Central PMCID: PMC3069751.
56. Joosten RP, Long F, Murshudov GN, Perrakis A, The PDB_REDO server for macromolecular structure model optimization. IUCrJ. 2014;1(Pt 4):213–20. doi: 10.1107/S2052252514009324 25075342; PubMed Central PMCID: PMC4107921.
57. Linke P, Amaning K, Maschberger M, Vallee F, Steier V, Baaske P, et al. An Automated Microscale Thermophoresis Screening Approach for Fragment-Based Lead Discovery. J Biomol Screen. 2016;21(4):414–21. doi: 10.1177/1087057115618347 26637553; PubMed Central PMCID: PMC4800460.
58. McNicholas S, Potterton E, Wilson KS, Noble ME, Presenting your structures: the CCP4mg molecular-graphics software. Acta Crystallogr D Biol Crystallogr. 2011;67(Pt 4):386–94. doi: 10.1107/S0907444911007281 21460457; PubMed Central PMCID: PMC3069754.
59. Vranken WF, Boucher W, Stevens TJ, Fogh RH, Pajon A, Llinas M, et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins. 2005;59(4):687–96. doi: 10.1002/prot.20449 15815974.
60. Christodoulides M, Brooks JL, Rattue E, Heckels JE, Immunisation with recombinant class 1 outer membrane protein from Neisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci. Microbiology. 1998;144:3027–37. doi: 10.1099/00221287-144-11-3027 9846738
61. Helal R, Melzig MF, Determination of lysozyme activity by a fluorescence technique in comparison with the classical turbidity assay. Pharmazie. 2008;63(6):415–9. 18604983.
62. Jespers L, Schon O, James LC, Veprintsev D, Winter G, Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold. J Mol Biol. 2004;337(4):893–903. doi: 10.1016/j.jmb.2004.02.013 15033359.
63. Rouet R, Dudgeon K, Christie M, Langley D, Christ D, Fully Human VH Single Domains That Rival the Stability and Cleft Recognition of Camelid Antibodies. J Biol Chem. 2015;290(19):11905–17. doi: 10.1074/jbc.M114.614842 25737448; PubMed Central PMCID: PMC4424330.
64. Ellison RT, 3rd, Giehl TJ, Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest. 1991;88(4):1080–91. doi: 10.1172/JCI115407 1918365; PubMed Central PMCID: PMC295557.
65. Ellison RT, 3rd, Giehl TJ, LaForce FM, Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect Immun. 1988;56(11):2774–81. 3169987; PubMed Central PMCID: PMC259649.